EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 383 filers reported holding EXELIXIS INC in Q1 2019. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $2,867,000 | +7.4% | 117,275 | +4.3% | 0.25% | -9.1% |
Q2 2020 | $2,669,000 | +397.9% | 112,445 | +311.9% | 0.27% | +878.6% |
Q4 2018 | $536,000 | +142.5% | 27,300 | +118.4% | 0.03% | +250.0% |
Q3 2018 | $221,000 | -86.3% | 12,500 | -76.4% | 0.01% | -66.7% |
Q4 2017 | $1,611,000 | -70.8% | 53,000 | -76.3% | 0.02% | -71.1% |
Q2 2017 | $5,517,000 | +69.5% | 224,000 | +49.1% | 0.08% | +69.4% |
Q1 2017 | $3,254,000 | +999.3% | 150,200 | +295.3% | 0.05% | +250.0% |
Q2 2016 | $296,000 | -64.5% | 38,000 | -81.8% | 0.01% | -65.0% |
Q1 2016 | $834,000 | +62.3% | 208,600 | +128.7% | 0.04% | +29.0% |
Q4 2015 | $514,000 | +188.8% | 91,200 | +31.4% | 0.03% | +82.4% |
Q1 2015 | $178,000 | +278.7% | 69,400 | +110.9% | 0.02% | +142.9% |
Q4 2014 | $47,000 | -2.1% | 32,900 | +4.4% | 0.01% | -22.2% |
Q3 2014 | $48,000 | -92.2% | 31,500 | -81.9% | 0.01% | -69.0% |
Q1 2014 | $614,000 | +859.4% | 173,600 | +1464.0% | 0.03% | +383.3% |
Q3 2013 | $64,000 | – | 11,100 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |